Development

Sun Pharma's ex-India biz at record low valuations, amid FDA troubles


… FDA ahead of the development. “1x EV/Sales (for the ex-India business) are distressed valuations. Sandoz sold its portfolio (declining sales) at 1x to …

To Read More, Please Visit Source

Related Articles

Back to top button
Close